Page 29 - CBAC Newsletter 2016

185. Gerlach U, Brendel J, Lang HJ, Paulus EF, Weidmann K, Bruggemann A, Busch AE, Suessbrich H, Bleich M,
Greger R. Synthesis and activity of novel and selective I(Ks)-channel blockers. J Med Chem.
186. 44, 3831-3837, 2001.
187.
Mall M, Bleich M, Schurlein M, Kuhr J, Seydewitz HH, Brandis M, Greger R, Kunzelmann K. Cholinergic ion
188. secretion in human colon requires coactivation by cAMP. Am J Physiol. 275, G1274-1281, 1998.
189.
190. Liu L, Wang F, Lu H, Ren X, Zou J. Chromanol 293B, an inhibitor of KCNQ1 channels, enhances glucose-
191. stimulated insulin secretion and increases glucagon-like peptide-1 level in mice. Islets 6,
e962386, 2014.
192.
193. Wei AD, Butler A, Salkoff L. KCNQ-like potassium channels in Caenorhabditis elegans. Conserved properties
and modulation. J Biol Chem. 280, 21337-21345, 2005.
194.
195. Seebohm G, Lerche C, Pusch M, Steinmeyer K, Bruggemann A, Busch AE. A kinetic study on the stereo-
196. specific inhibition of KCNQ1 and I(Ks) by the chromanol 293B. Br J Pharmacol. 134, 1647-1654, 2001.

197. Karam R, Marcello S, Brooks RR, Corey AE, Moore A. Azimilide dihydrochloride, a novel antiarrhythmic agent.
198. Am J Cardiol. 81, 40D-46D, 1998.
199.
Busch AE., Malloy K, Groh WJ, Varnum MD, Adelman JP, Maylie J. The novel class III antiarrhythmics
200. NE-10064 and NE-10133 inhibit IsK channels expressed in Xenopus oocytes and IKs in guinea pig
201. cardiac myocytes. Biochem Biophys Res Commun. 202, 265-270, 1994.
202.
203. Chen F, Esmailian F, Sun W, Wetzel GT, Sarma JS, Singh BN, Klitzner TS. Azimilide inhibits multiple cardiac
potassium currents in human atrial myocytes. J Cardiovasc Pharmacol Ther. 7, 255-264, 2002.

Davies MP, Freeman LC, Kass RS. Dual actions of the novel class III antiarrhythmic drug NE-10064 on
delayed potassium channel currents in guinea pig ventricular and sinoatrial node cells.
J Pharmacol Exp Ther. 276, 1149-1154, 1996.

Clancy CE, Kurokawa J, Tateyama M, Wehrens XH, Kass RS. K+ channel structure-activity relationships and
mechanisms of drug-induced QT prolongation. Annu Rev Pharmacol Toxicol. 43, 441-461, 2003.

Toyoda F, Ueyama H, Ding WG, Matsuura H. Modulation of functional properties of KCNQ1 channel by
association of KCNE1 and KCNE2. Biochem Biophys Res Commun. 344, 814-820, 2006.

Black SC, Butterfield JL, Lucchesi BR. Protection against Programmed Electrical Stimulation-Induced
Ventricular-Tachycardia and Sudden Cardiac Death by Ne-10064, a Class-Iii Antiarrhythmic Drug.
J Cardiovasc Pharm. 22, 810-818, 1993.

Tatla DS, David BC, Malloy KJ, Moorehead TJ. Invitro Electrophysiology of Ne-10064, a Novel and Highly
Selective Class-Iii Antiarrhythmic Agent. Faseb J. 7, A107-A107, 1993.

Brandt MA, Maynard AE. Ne-10064 Exhibits Class-Iii Antiarrhythmic Effects after Intravenous or
Oral-Administration in Conscious Dogs. Faseb J. 8, A7-A7, 1994.

Mcintosh MA, Tanira M, Pacini D, Kane KA. Comparison of the Cardiac Electrophysiologic Effects of
Ne-10064 with Sotalol and E-4031 and Their Modification by Simulated Ischemia. J Cardiovasc Pharm.
23, 653-657, 1994.

Tamargo J, Caballero R, Gomez R, Valenzuela C, Delpon E. Pharmacology of cardiac potassium channels.
Cardiovasc Res. 62, 9-33, 2004.

Busch AE, Malloy KJ, Varnum MD, Adelman JP, North RA, Maylie J. A Slowly-Activating Potassium Current I(Ks)
Is the Target for the Class-Iii Antiarrhythmic Drug Ne-10064. Circulation. 88, 231-231, 1993.

Conder ML, Smith MA, Atwal KS, Mccullough JR. Effects of Ne-10064 on K+ Currents in Cardiac-Cells.
Biophys J. 66, A326-A326, 1994.

Selnick HG, Liverton NJ, Baldwin JJ, Butcher JW, Claremon DA, Elliott JM, Freidinger RM, King SA, Libby BE,
McIntyre CJ, Pribush DA, Remy DC, Smith GR, Tebben AJ, Jurkiewicz NK, Lynch JJ, Salata JJ,
Sanguinetti MC, Siegl PK, Slaughter DE, Vyas K. Class III antiarrhythmic activity in vivo by
selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by

CBAC Center Heartbeat | 25